Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...